These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 17169119)

  • 1. A recombinant protein LHRH-PE40 for tumour therapy: preclinical safety studies.
    Li J; Sun Y; Zhang J
    Basic Clin Pharmacol Toxicol; 2006 Dec; 99(6):398-404. PubMed ID: 17169119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological hormone atrophy by gonadotropin-based drug.
    Li J; Zhang J
    Int J Exp Pathol; 2006 Dec; 87(6):495-9. PubMed ID: 17222217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BR96 sFv-PE40 immunotoxin: nonclinical safety assessment.
    Haggerty HG; Warner WA; Comereski CR; Peden WM; Mezza LE; Damle BD; Siegall CB; Davidson TJ
    Toxicol Pathol; 1999; 27(1):87-94. PubMed ID: 10367679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ability of luteinizing hormone releasing hormone-Pseudomonas aeruginosa exotoxin 40 binding to LHRH receptor on human liver cancer cells.
    Gong SL; Zhao G; Zhao HG; Lu WT; Liu GW; Zhu P
    World J Gastroenterol; 2004 Oct; 10(19):2870-3. PubMed ID: 15334689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation of recombinant atoxic form of exotoxin A from Pseudomonas aeruginosa.
    Kaloshin AA; Isakov MA; Mikhailova NA; Vertiev JV
    Bull Exp Biol Med; 2013 Jan; 154(3):346-50. PubMed ID: 23484197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs.
    Siegall CB; Liggitt D; Chace D; Mixan B; Sugai J; Davidson T; Steinitz M
    Clin Cancer Res; 1997 Mar; 3(3):339-45. PubMed ID: 9815690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of LHRH-PE40 on target cells via LHRH receptors.
    Deng X; Klussmann S; Wu GM; Akkerman D; Zhu YQ; Liu Y; Chen H; Zhu P; Yu BZ; Zhang GL
    J Drug Target; 2008 Jun; 16(5):379-88. PubMed ID: 18569282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo characterization of BR96 sFv-PE40. A single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats.
    Siegall CB; Chace D; Mixan B; Garrigues U; Wan H; Paul L; Wolff E; Hellström I; Hellström KE
    J Immunol; 1994 Mar; 152(5):2377-84. PubMed ID: 8133048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basic fibroblast growth factor-Pseudomonas exotoxin chimeric proteins; comparison with acidic fibroblast growth factor-Pseudomonas exotoxin.
    Gawlak SL; Pastan I; Siegall CB
    Bioconjug Chem; 1993; 4(6):483-9. PubMed ID: 7508267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts.
    Friedman PN; Chace DF; Trail PA; Siegall CB
    J Immunol; 1993 Apr; 150(7):3054-61. PubMed ID: 8454873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxicity of IL6-PE40 and derivatives on tumor cells expressing a range of interleukin 6 receptor levels.
    Siegall CB; FitzGerald DJ; Pastan I
    J Biol Chem; 1990 Sep; 265(27):16318-23. PubMed ID: 2118904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on the activity of barnase toxins in vitro and in vivo.
    Prior TI; Kunwar S; Pastan I
    Bioconjug Chem; 1996; 7(1):23-9. PubMed ID: 8741987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular distribution of the chimeric protein IL2-PE40.
    BenEzra D; Maftzir G; Hochberg E; Anteby I; Lorberboum-Galski H
    Curr Eye Res; 1995 Feb; 14(2):153-8. PubMed ID: 7768107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transforming growth factor alpha-Pseudomonas exotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts.
    Heimbrook DC; Stirdivant SM; Ahern JD; Balishin NL; Patrick DR; Edwards GM; Defeo-Jones D; FitzGerald DJ; Pastan I; Oliff A
    Proc Natl Acad Sci U S A; 1990 Jun; 87(12):4697-701. PubMed ID: 2352944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LHRH-PE40-Induced Vascular Leak Syndrome.
    Li J; Zhang JK
    Toxicol Mech Methods; 2006; 16(8):473-6. PubMed ID: 20021022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model.
    Kreitman RJ; Chang CN; Hudson DV; Queen C; Bailon P; Pastan I
    Int J Cancer; 1994 Jun; 57(6):856-64. PubMed ID: 8206679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute and subchronic toxicity studies with detirelix, a luteinizing hormone-releasing hormone antagonist, in the rat and monkey.
    Chester AE; Fairchild DG; Depass LR
    Fundam Appl Toxicol; 1991 Oct; 17(3):505-18. PubMed ID: 1794654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys.
    Pai LH; Batra JK; FitzGerald DJ; Willingham MC; Pastan I
    Cancer Res; 1992 Jun; 52(11):3189-93. PubMed ID: 1591729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudomonas aeruginosa exotoxin A-induced hepatotoxicity: an animal model in rats.
    Chiu CC; Chen HH; Chuang HL; Chung TC; Chen SD; Huang YT
    J Vet Med Sci; 2009 Jan; 71(1):1-8. PubMed ID: 19194069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma.
    Puri RK; Hoon DS; Leland P; Snoy P; Rand RW; Pastan I; Kreitman RJ
    Cancer Res; 1996 Dec; 56(24):5631-7. PubMed ID: 8971168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.